2024 Partners


Expertise Partner

We share your passion for science. Promega is committed to excellence in technologies to assess key processes in Targeted Protein Degradation and Induced Proximity mechanisms. From assessing protein degradation in real time, to understanding compound binding and permeability, to ternary complex formation and more. Our CRISPR content covers hundreds of pre-built targets. Assay live cells in kinetic mode to determine target protein degradation rates, DC50 potency values, and recovery profiles. Let’s collaborate.


Here is What Some of the Leaders of the Field Have to Say About this Meeting:

‘This meeting provides a great platform for people working in the cutting-edge of the molecular glue field to exchange ideas and inspire new collaborations’

Kun Song, Associate Principal Scientist- Computational Chemistry, AstraZeneca 

‘This is a unique opportunity to showcase Plexium’s unique high-throughput and high-dimensional approach to unbiased identification of E3 ligase redirection events, in the context of industry leaders in the field of TPD’,

Tomas Duffy, Principal Scientist, Plexium

‘This meeting is an excellent opportunity to hear the latest relevant research, reconnect with previous co-workers, and meet new colleagues, all of which facilitate initiating partnerships to accelerate scientific and therapeutic discoveries’

Ingrid Wertz, Chief Executive Officer & Co-Founder, Lyterian Therapeutics

‘As recent advances of degrading molecular glues from the bench to the clinic significantly expand the druggable target space, the discussion topics of non-degrading and stabilizing molecular glues come at an opportune time to further stir up interests of these approaches that will further expand the arsenal of the drug discovery community to target the “undruggable” space’

Yongxin Han, Executive Vice President & Head of Drug Discovery, Nested Therapeutics